使用Wynzora乳膏应该注意什么？

is a cream-based fixed-dose combination of calcipotriol and betamethasone dipropionate for the treatment of mild to moderate plaque psoriasis, including scalp areas, in adults 18 years of age and older. Wynzora is highly effective and works quickly within 1 week. Once a day, apply externally to the affected area for 8 weeks, no more than 100 grams per week. When plaque psoriasis is under control, patients should stop treatment. However, you should also pay attention to the following things while using Wynzora Cream:

Hypercalcemia and hypercalciuria

Hypercalcemia and hypercalciuria have been observed with topical calcipotriene. If hypercalcemia or hypercalciuria occurs, discontinue treatment until calcium metabolism parameters return to normal.

Effects on the endocrine system

1. Hypothalamic-pituitary-adrenal axis suppression: WYNZORA cream can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, which may lead to clinical glucocorticoid deficiency. HPA axis suppression can be assessed by using the adrenocorticotropic hormone (ACTH) stimulation test. If HPA axis suppression is documented, gradually discontinue WYNZORA cream, reduce frequency, or replace it with a less potent corticosteroid.

2. Cushing's syndrome and hyperglycemia: The systemic effects of topical corticosteroids may lead to Cushing's syndrome and hyperglycemia. These complications often occur after prolonged exposure to excessive doses, especially of highly potent topical corticosteroids.

3. Additional considerations for endocrine adverse reactions: Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface relative to body mass. Concurrent use of multiple corticosteroid-containing products may increase systemic corticosteroid exposure.

Allergic contact dermatitis caused by topical corticosteroids

Contact dermatitis allergic to topical corticosteroids is usually diagnosed by observing failure to heal rather than clinical deterioration. Such observations should be confirmed by appropriate diagnostic patch testing.

Allergic contact dermatitis induced by topical calcipotriene

Allergic contact dermatitis has been observed with topical calcipotriene. Such observations should be confirmed by appropriate diagnostic patch testing.

Ophthalmic adverse reactions

Use of topical corticosteroids, including WYNZORA cream, may increase the risk of glaucoma and posterior subcapsular cataracts. Cataracts and glaucoma have been reported with postmarketing use of topical corticosteroid products.

Avoid contact with WYNZORA cream in eyes. WYNZORA Cream may cause eye irritation. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation.

Recommended hot articles: